Sydney Jennings

Articles

Atopic Dermatitis: Investigational Anti-OX40L Antibody Shows Sustained Itch Relief, Even After Discontinuation

March 08, 2025

AAD 2025: In a post hoc analysis of the STREAM-AD Phase 2b study, 63% of patients with AD maintained itch reduction even after stopping amlitelimab use.

Tapinarof Cream 1% Demonstrates Sustained Disease Control in Adults, Children with Atopic Dermatitis

March 08, 2025

AAD 2025: New analysis of the ADORING 3 trial showed tapinarof maintains low disease activity in patients with AD for an average of 79.8 days post-treatment.

Bimekizumab Demonstrates Sustained Efficacy in Moderate-to-Severe Plaque Psoriasis Over Five Years

March 07, 2025

AAD 2025. New research indicates that dual inhibition of IL-17A and IL-17F with bimekizumab maintains high rates of complete skin clearance for up to 5 years.

Patient Benefit Index Complements Traditional Psoriasis Outcome Measures, Study Finds

March 06, 2025

Findings showed that improved skin clearance and reduced anxiety and depression significantly influenced perceived patient benefit.

Depemokimab Shows Significant Improvements in Rhinosinusitis with Nasal Polyps: New Research

March 05, 2025

AAAAI 2025: Data from the ANCHOR-1 and ANCHOR-2 phase 3 trials show improvements in nasal polyp size and obstruction for depemokimab with twice-yearly dosing vs placebo.

Study Reveals Persistent Telehealth Disparities in Depression Management: Daily Dose

March 05, 2025

Your daily dose of the clinical news you may have missed.

Dupilumab Shows Efficacy in Eosinophilic Esophagitis Regardless of Food Elimination Diets

March 04, 2025

The impact of food elimination diets on medication previously was unknown, according to new research presented at AAAAI 2025.

Shifting Trends in Severe Asthma Biologics: Daily Dose

March 04, 2025

Your daily dose of the clinical news you may have missed.

GSK’s Depemokimab Applications Accepted for FDA Review for Asthma and CRSwNP

March 03, 2025

If approved, depemokimab will be the first ultra-long-acting biologic with 6-month dosing, according to GSK.

FDA Approves First Rapid-Acting Insulin Biosimilar for Diabetes: Daily Dose

March 03, 2025

Your daily dose of the clinical news you may have missed.